April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Quantitative Proteomic Analysis of Dexamethasone-Treated Human Trabecular Meshwork Cells
Author Affiliations & Notes
  • J. S. Crabb
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
  • K. E. Bollinger
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
  • X. Yuan
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
  • X. Yue
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
  • A. F. Clark
    Cell Biology & Genetics, University of North Texas HSC, Fort Worth, Texas
  • J. W. Crabb
    Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  J.S. Crabb, None; K.E. Bollinger, None; X. Yuan, None; X. Yue, None; A.F. Clark, None; J.W. Crabb, Allergan, Inc, C.
  • Footnotes
    Support  American Health Assistance Foundation, NIH grants EY018147, EY14239, EY15638, Research to Prevent Blindness (RPB) Challenge Grant, RPB Senior Investigator Award, and the Cleveland Clinic Foundation
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3206. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. S. Crabb, K. E. Bollinger, X. Yuan, X. Yue, A. F. Clark, J. W. Crabb; Quantitative Proteomic Analysis of Dexamethasone-Treated Human Trabecular Meshwork Cells. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3206. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Corticosteroids are commonly used anti-inflammatory drugs that can increase intraocular pressure and cause secondary glaucoma. Toward better understanding the mechanisms underlying steroid-induced glaucoma, we evaluated quantitative proteomic changes in cultured trabecular meshwork (TM) cells following dexamethasone-treatment.

Methods: : Primary cultures of human TM cells from 2 glaucomatous and 2 non-glaucomatous donors were treated with or without dexamethasone (100 nM) for 10 days. Protein was extracted, digested with trypsin, peptides labeled with iTRAQ tags, and dexamethasone-treated TM samples were combined with their corresponding untreated samples. Following strong cation exchange chromatography, peptides were analyzed by LC MS/MS and proteins were identified using the Mascot search engine and the Swiss-Protein database. Relative protein quantification from iTRAQ labeling utilized code written in R. Immunoblotting was used to corroborate differential expression of select proteins.

Results: : A total of 718 proteins were quantified with 2 or more peptides from dexamethasone-treated TM cells. No definitive proteomic differences were detected between glaucomatous and control TM cells. Among proteins quantified in at least 3 of the 4 TM samples, the abundance of 20 proteins increased and 20 proteins decreased significantly with dexamethasone-treatment. Sorbin and SH3 domain-containing protein 2, nexilin, and CD166 antigen were the most significantly elevated, while collagen α-1(I), serpin H1, and UDP-glucose 6-dehydrogenase were the most significantly decreased proteins.

Conclusions: : Dexamethasone-induced increased protein expression could alter TM cell adhesion, cell migration and cytoskelatal organization while reduced protein expression could compromise the structural integrity of the ECM associated with the TM. These results suggest that such proteomic changes could contribute to aqueous outflow resistance in the TM and may play a role in the molecular mechanisms of glaucoma pathology.

Keywords: trabecular meshwork • proteomics • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×